Denali Therapeutics (NASDAQ:DNLI) had its price target lowered by analysts at Wedbush from $31.00 to $30.00. They now have an "outperform" rating on the stock.
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants